99 results about "CMV Pneumonia" patented technology

Methods and compositions comprising isolated nucleic acid molecules specific to Streptococcus pneumoniae and Streptococcus pyogenes, as well as vector constructs and isolated polypeptides specific to Streptococcus pneumoniae and Streptococcus pyogenes are provided. Such compositions and methods are useful for the diagnosis of Streptococcal infection and for generating an immune response to Streptococcal bacteria.

The invention discloses a strong lysis bacteriophage for splitting NDM-1 positive Klebsiella pneumoniae clinical isolates, and an application of the strong lysis bacteriophage used as a biological preparation in the prevention and treatment of NDM-1 Klebsiella pneumoniae induced infection and pollution. The preservation number of the bacteriophage is CCTCC M 2015760, and the bacteriophage has a regularly icosahedral head and a telescopic tail, and belongs to a Myoviridae double-stranded DNA bacteriophage. The bacteriophage has strong kilign activity and wide bacteriophage lysis spectrum, can be used for preparing medicines for preventing and treating NDM-1 Klebsiella pneumoniae induced bacterium infection, and also can be used for killing NDM-1 positive Klebsiella pneumoniae in culture environment and medical environment.

A method and apparatus for the diagnosis of hospital-acquired pneumonia is described. The method uses the analysis of volatile organic compounds (VOCs) in exhaled breath that indicate pneumonia or the presence of pathogens in the respiratory tract in intubated and mechanically ventilated intensive care unit patients. The apparatus may be an electronic nose incorporated into a ventilation system, which outputs to a display the indication of pneumonia. One particular useful VOC is 1-propanol.

The invention relates to the technical field of biology, disclosing two pseudomonas aeruginosa virulent strains and a mink hemorrhagic pneumonia divalent inactivated vaccine prepared from the two strains. The pseudomonas aeruginosa virulent strains are inoculated in a culture medium to be amplified and cultured by ventilation; after the obtained cultured object is inactivated, the products are mixed at the ratio of 1-2:1; and adjuvant is added to prepare the mink hemorrhagic pneumonia divalent inactivated vaccine. The divalent inactivated vaccine disclosed by the invention has good immunity effect on mink hemorrhagic pneumonia, at least five-month protection periods can be obtained, the protection ratio is above 80%, the mink hemorrhagic pneumonia can be prevented, and the vaccine has good application prospect.

The invention discloses an application of a compound to preparation of medicines for treating viral pneumonia, and relates to the technical field of drugs. The technical problem that novel antiviral drugs are deficient in the prior art, can be solved. The compound comprises a purine compound adopting the structure as shown in the formula 1, and / or an anthraquinone derivative adopting the structureas shown in the formula 2. The purine compound adopting the structure as shown in the formula 1, and / or the anthraquinone derivative adopting the structure as shown in the formula 2 both can show predominant effect for resisting viral pneumonia when being separately used or used jointly. Drugs for treating viral pneumonia, are prepared by the compound provided by the invention are more notable inactivity compared with clinical frontline drugs, and are better than drugs of ribavirin, oseltamivir and the like.

Macrolide resistance associated with macrolide efflux (mef) in Streptococcus pneumoniae has been defined with respect to the genetic structure and dissemination of a novel mefE-containing chromosomal insertion element. The mefE gene is found on the 5′-end of a 5.5 kb or 5.4 kb insertion designated mega (macrolide efflux genetic assembly) found in at least four distinct sites of the pneumococcal genome. The element is transformable and confers macrolide resistance to susceptible S. pneumoniae. The first two open reading frames (ORFs) of the element form an operon composed of mefE and a predicted ATP-binding cassette homologous to msrA. Convergent to this efflux operon are three ORFs with homology to stress response genes of Tn5252. Mega is related to mefA-containing element Tn1207.1. Macrolide resistance due to mega has been rapidly increased by clonal expansion of bacteria containing it and horizontally by transformation of previously sensitive bacteria.

The invention relates to an anti-coronavirus traditional Chinese medicine composition as well as a preparation method and application thereof. The traditional Chinese medicine composition comprises traditional Chinese medicine active extract, and the active extract consists of first extract and second extract. The first extract is an aqueous extract or an alcohol-water extract of ephedra, semen armeniacae amarae, gypsum, semen coicis, rhizoma atractylodis, pogostemon cablin, polygonum cuspidatum, verbena, rhizoma phragmitis, semen lepidii, exocarpium citri grandis and artemisia apiacea, and the second extract is an aqueous extract or an alcohol-water extract of liquorice. The first extract and the second extract are independently extracted. The traditional Chinese medicine composition canbe used for treating coronavirus diseases such as novel coronavirus pneumonia.

The invention discloses an anti-SARS coronavirus cell vaccine and its application, said cell vaccine (1) containing all or part gene fragment of SARS coronavirus S protein all length gene order and 5 specific eukaryotic expression vector of cDNA fragment; (2) expressing the heterogenetic antigen presenting cells of said SARS coronavirus gene corresponding protei; (3) inactivating the heterogenetic antigen presenting cells expressing SARS coronavirus related protein. Use said cell vaccine for immuning host containing humans and rodents such as mice in order to making them generate protective humoral immunity and cellular immunity and resisting the SARS coronavirus infection which causes atypical pneumonia contagion. The security and stability of the invention are fine, production is convenient and price is low, it can induce the body generating the effective humoral immunity and cellular immunity of SARS coronavirus causing atypical pneumonia at the same time; provide effective and cheap vaccines for treating and preventing SARS.

The invention relates to a traditional Chinese medicine composition used for treating respiratory diseases and related inflammatory conditions, and a preparation method and use of the traditional Chinese medicine composition. The traditional Chinese medicine composition contains traditional Chinese medicine active extracts. The respiratory diseases include pneumonia, trachitis, bronchitis, chroniccough, asthma, chronic obstructive pulmonary diseases and the like. The traditional Chinese medicine composition in the invention is particularly suitable for treating viral pneumonia and related inflammatory conditions, in particular coronavirus pneumonia, such as novel coronavirus pneumonia (COVID-19).

The invention discloses a lytic klebsiella pneumoniae bacteriophage RDP-KP-20005, and a host of the bacteriophageis klebsiella pneumoniae BK-20005; the head of the bacteriophage is icosahedron, and is 92.281 nm long, and the bacteriophage is in cubic symmetry and has a short tail, the tail length is 107.442 nm; the bacteriophage belongs to caudovirales podoviridae, the gene full length is48585bp; the bacteriophage does not have a virulence gene or alysogenic gene; and the bacteriophage is collected in China General Microbiological Culture Collection Center on December 17, 2020, and the collection number is CGMCC No. 21408. The bacteriophage can effectively decompose klebsiella pneumoniae, and can effectively and rapidly kill cracking bacteria to prevent and control propagation and proliferation of the klebsiella pneumoniae.

The invention provides a traditional Chinese medicine composition and application thereof in prevention and treatment of viral pneumonia. According to the traditional Chinese medicine composition, 40-130 parts of fructus forsythiae, edible tulip, honeysuckle, scutellaria baicalensis and folium isatidis are used as basic components, and 50-110 parts of a qi-tonifying yin-nourishing component, 20-50parts of a spleen-tonifying circulation-assisting component, 15-50 parts of a phlegm-heat-clearing component, 14-50 parts of a phlegm-eliminating masses-resolving component and 20-50 parts of a lung-promoting, lung-moistening, lung-astringing and asthma-preventing component which accord with incompatibility of traditional Chinese medicines are matched. The traditional Chinese medicine compositionhas the effects of clearing away heat and toxic materials, dispelling wind and promoting exterior syndrome, relieving cough and reducing sputum and tonifying qi and yin, is suitable for treating thenovel coronavirus pneumonia, can effectively relieve symptoms of patients with the novel coronavirus pneumonia and improve prognosis, reduces the diseaseseverity-causing rate and the case fatality rate, and is clear and remarkable in curative effect.

The invention belongs to the technical field of traditional Chinese medicines, and relates to a dampness-clearing lung-ventilating traditional Chinese medicine composition. The traditional Chinese medicine composition comprises the following components in parts by mass: 5 to 10 parts of raw ephedra herb, 25 to 30 parts of gypsum, 5 to 12 parts of semen armeniacae amarae, 10 to 16 parts of rhizomaanemarrhenae, 10 to 16 parts of radix bupleuri chinensis, 10 to 16 parts of rhizoma seu radix notopterygii, 10-16 parts of rhizoma atractylodis, 10-16 parts of wrinkled gianthyssop herb and 5-12 partsof medicated leaven. The invention further provides application of the dampness-clearing lung-ventilating traditional Chinese medicine composition in preparation of a medicine for treating community-acquired pneumonia, especially viral pneumonia or suspected COVID-19. The dampness-clearing lung-ventilating traditional Chinese medicine composition of the invention can be used as a medicine for treating suspected cases of COVID-19 to cut off and reverse an illness state in an early stage and prevent deterioration and development of the illness state.

The invention discloses an application of heterocyclic compounds in preparation of medicines for treating pneumonia, and relates to the technical field of biomedicine. According to the application ofthe heterocyclic compounds in the preparation of the medicines for treating the pneumonia provided by the invention, the heterocyclic compounds have anti-pneumonia activity, wherein the pneumonia includes but is not limited to viral pneumonia, bacterial pneumonia, mycoplasma pneumonia, and chlamydia pneumonia. The anti-pneumonia pharmacological activity of the structurally modified and transformedheterocyclic compounds is tested, the pharmacological activity of the compounds is tested in multiple pneumonia models, and data of anti-pneumonia activity are provided to confirm that the heterocyclic compounds all have excellent anti-pneumonia activity, that is, the heterocyclic compounds with antipneumonia activity are screened out, so that a novel skeleton can be provided for screening a novel compound for treating the pneumonia, and a theoretical foundation is laid for development of a novel lead compounds.

The invention relates to a traditional Chinese medicine composition suitable for viral cold and viral pneumonia as well as an administration mode and preparation of the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from the following traditional Chinese medicine raw materials in parts by weight. 5-15 parts of ginseng, 5-15 parts of astragalus membranaceus, 5-15 parts of notopterygium root, 5-15 parts of radix angelicae pubescentis, 5-15 parts of ligusticum wallichii, 5-15 parts of radix bupleuri, 5-15 parts of platycodon grandiflorum, 5-15 parts of fructus aurantii, 5-15 parts of radix peucedani, 5-15 parts of poria cocos, 5-15 parts of honeysuckle, 5-15 parts of fructus forsythiae, 5-15 parts of rhizoma atractylodis, 2-10 parts of liquorice, 1-5 parts of mint and 1-9 parts of rhizoma zingiberis.

The invention discloses a high-lysis klebsiella pneumoniae bacteriophage RKP-KP-20007 and application thereof, the host of the high-lysis klebsiella pneumoniae bacteriophage RKP-KP-20007 is klebsiella pneumoniae, observation through an electron microscope shows that the head of the bacteriophage is an eicosahedron and is in stereo symmetry, the length of the head is 72.640 nm, the length of the tail of the bacteriophage is 177.797 nm, the bacteriophage is a long-tail bacteriophage family with the tail, and the preservation number is CGMCC No. 22495. The Klebsiella pneumoniae bacteriophage RKP-KP-20007 has a strong cracking effect on Klebsiella pneumoniae in a poultry breeding environment, can be used for efficiently treating Klebsiella pneumoniae diseases caused by pathogenic bacteria in poultry breeding, and can be used as a disinfectant. A bacteriophage source is provided for industrial, large-scale and programmed production of bacteriophages and treatment of poultry breeding bacterial diseases caused by klebsiella pneumoniae.

Ventilator associated pneumonia (VAP) may be prevented in a patient, or its occurrence reduced in a population of patients, by using an anti-VAP device or an anti-VAP material such as an anti-VAP mouthpiece that absorbs secretions. By reducing the problem of bacterial-containing secretions that otherwise build up in the airway of, and elsewhere in, the intubated patient, VAP can be prevented from occurring in intubated patients, such as patients intubated with an endotracheal tube (ETT) or a nasogastric tube. Anti-VAP mouthpieces also are useable in non-intubated patients to maintain oral hygiene.

The invention discloses a novel bacteriophage, a bacteriophage mixed formulation and an application of the novel bacteriophage and an application of the bacteriophage mixed formulation to prevention and treatment of pseudomonas pneumonia of minks. The novel bacteriophage is klebsiella pneumoniae bacteriophage vB_KpnM_PH35 of which the preservation No. is CGMCC NO.18858, the bacteriophage mixed formulation comprises a klebsiella pneumoniae bacteriophage vB_KpnM_PH35 of which the preservation No. is CGMCC NO.18858 and a pseudomonas aeruginosa bacteriophage vB_PaeS_PA69 of which the preservationNo. is CGMCC NO.18855. The novel bacteriophage and the bacteriophage mixed formulation have broad spectrum sterilization effects, the sterilizing scope is greatly widened, the bactericidal activity isimproved, and the cure rate of the minks can be greatly increased. Through mouse test, the bacteriophage mixed formulation is free from toxic and side effects, high in safety and convenient for large-scale production. The bacteriophage mixed formulation has good hydrophilic phase, and is easy to make into spraying liquid or injections, and klebsiella pneumoniae and pseudomonas aeruginosa in environment can be effectively killed.

The invention provides an extracting method for extracting desertliving cistanche alcohol extracts in desertliving cistanche peel, a desertliving cistanche alcohol extract obtained according to the method, and use of the desertliving cistanche alcohol extract. The method comprises the following steps: using the desertliving cistanche peel, baking and crushing the desertliving cistanche peel, and performing ultrasonic extraction, ultrafiltration and purification, so as to obtain the desertliving cistanche alcohol extract of which the molecular weight is smaller than 5000 Dalton; performing concerted application on the desertliving cistanche alcohol extract, radish seeds, rhizoma coptidis, Chinese rhubarb, phellodendron, radix salviae miltiorrhizae, rhizoma polygonati, glossy privet fruits and the like, so as to obtain the medical composition disclosed by the invention; researching the medical composition in the respects of treating and preventing radioactive pneumonia for postradiotherapy, improving the organism immunity, and the like. The extracting method disclosed by the invention increases the utilization of desertliving cistanche which belongs to the rare medicinal materials in imminent danger, so that the desertliving cistanche has a higher economic value, and the extracting method provides a medical composition which has the advantages of high efficiency, low toxicity and low cost, and is easy to generalize for vast patients with tumors.

The invention relates to the field of biotechnology, in particular to strains, application of the strains, a vaccine and a preparation method of the vaccine, and provides a combined inactivated vaccine for mink parvoviral enteritis and hemorrhagic pneumonia and a preparation process of the combined inactivated vaccine. The (bacterium) virus strains of the vaccine include the mink enteritis parvovirus strain (MEVB strain) and the mink pseudomonas aeruginosa G-type DL15 strain, B-type JL08 strain, C-type WD01 strain, I-type WF05 strain and F-type DL03 strain which are popular in China. The parvoviral enteritis strain and the pseudomonas aeruginosa strains serving as antigens are cultured, inactivated with formaldehyde and then mixed in proportion, aluminium hydroxide colloid is added in proportion, and the vaccine is prepared. The immunity period of the vaccine is 6 months, the immunity protection rate is 80% or above, and the vaccine can be used for preventing mink parvoviral enteritis and mink hemorrhagic pneumonia at the same time, reduces the immunization workload of raising households and the stress response of minks and has good market application prospects.

The invention provides an application of licorice flavonoids in preparing antitussives for treating acute and chronic cough caused by a plurality of reasons. The related acute and chronic cough comprises cough symptoms caused by various diseases such as acute and chronic tracheitis, asthma, chronic obstructive disease of lung, idiopathic pulmonary fibrosis, tuberculosis, bacterial pneumonia, bronchiectasis and the like. The licorice flavonoids extracted from liquorice proves to have very strong effect in preventing cough according to pharmacological tests; drug potency thereof is similar to the drug potency of codein in narcotic antitussive; the function mechanism analyses indicate that the licorice flavonoids plays the role of preventing cough through the non-narcotic nerve centre. In addition, the licorice flavonoids extracted from natural plants can also be prepared into health food. The invention solves the problem that the non-narcotic potent antitussives are badly needed, provides a non-narcotic potent antitussives which has fine social and economical benefits.

The invention relates to a production method of semen lepidii and fructus jujubae lung purging granules, in particular to production of semen lepidii and fructus jujubae lung purging granules from twobulk medicine materials of fructus jujubae and semen lepidii through technologies of pretreatment, decoction, decotion with stir-fried semen lepidii wrapped, filtering, concentration, drying, granulation and the like, and belongs to the field of traditional Chinese medicine preparations. The obtained semen lepidii and fructus jujubae lung purging granules have the efficacy of purging the lung, inducing diuresis, descending qi and dissolving phlegm, and are used for treating respiratory system disease of pulmonary heart disease, emphysema, wet pleurisy, lobar pneumonia, bronchial asthma, chronic bronchitis, pertussis and the like, the recipe is simple, however, the semen lepidii and fructus jujubae lung purging granules have significantly-curative and excellent effects. According to production of the semen lepidii and fructus jujubae lung purging granules from the two bulk medicine materials of the fructus jujubae and the semen lepidii through the technologies of pretreatment, decoction, decotion with the stir-fried semen lepidii wrapped, filtering, concentration, drying, granulation and the like, by conducting dosage form reform and innovation on traditional Chinese medicine decotion, the problems that production, taking and carrying are inconvenient, and the like can be effectively solved, the production method of the semen lepidii and fructus jujubae lung purging granules isscientific and reasonable, the materials for efficacy are kept furthest, and large-scale production is easy, so that the production method of the semen lepidii and fructus jujubae lung purging granules has significant economic benefits and application prospects.

Galectin 3 inhibitors and methods for treating sepsis using the same are provided herein.

The invention relates to an application of a compound acetylshikonin in preparation of a medicine for resisting lung inflammatory factor storm, namely an inhibition effect of acetylshikonin on mouse acute lung injury and inflammatory factor storm induced by polyinosinic-cytidylic acid and SARS-CoV-2 spinous process protein. The compound acetylshikonin can inhibit inflammatory factors induced by polyinosinic-cytidylic acid and SARS-CoV-2 spinous process protein, obviously inhibits expression of interleukin IL-6 in inflammatory reaction, and can be further applied to research and development of drugs for treating or preventing lung inflammation. The acetylshikonin is suitable for treating lung inflammatory factor storm and acute lung injury caused by viral pneumonia, bacterial pneumonia, mycoplasma pneumonia and the like.

The invention discloses a novel application of white hyacinth beans. The white hyacinth beans are used for preventing and treating epidemic diseases which are positive by nucleic acid testing. The principle of nucleic acid testing is that a reverse transcription-polymerase chain reaction (RT-PCR) method is adopted, and research finds that the white hyacinth beans contain rich dolichin antibacterial proteins and has the antiviral effect on viruses sensitive by adopting a reverse transcription detection method, so that the white hyacinth beans have the obvious treatment effects on infected persons who are positive by nucleic acid testing of novel coronavirus pneumonia COVID-19, atypical pneumonia SARS and the like, have clinic symptoms of cough, fever, weakness, diarrhea, inappetence, palpitation, nausea, vomiting, constipation and the like, and have no symptoms; meanwhile, white hyacinth bean polysaccharides contained in the white hyacinth beans can also improve the immune function of the human body; and the white hyacinth beans belong to medicinal and edible articles and therefore are also suitable for daily prevention.

The invention discloses rabbit staphylococcus aureus and application thereof in preparation of an inactivated vaccine. A strain of staphylococcus aureus SA472 with strong pathogenicity to rabbits is screened from suppurative pneumonia lung samples, mastitis samples and foot dermatitis samples of multiple dead rabbits through bacterial isolation and identification and animal regression tests, and the preservation number of the staphylococcus aureus SA472 is CCTCC NO: M 2021200. The invention also discloses an application of the staphylococcus aureus SA472 in preparation of an inactivated vaccine, which comprises the following steps of: carrying out enlarged culture on the strain to obtain a bacterial solution, inactivating the bacterial solution to obtain an inactivated bacterial solution, adding an adjuvant, and uniformly mixing to obtain an inactivated vaccine. The inactivated vaccine disclosed by the invention is high in safety, the titer of an antibody generated after immunization is high, and the occurrence of staphylococcus aureus infected rabbits can be effectively prevented.

The invention discloses exosomes generated by mesenchymal stem cells treated by IL18, IL12 and IL15 and antiviral application of the exosomes, and relates to the technical field of biological medicines. The exosome is generated by pretreating mesenchymal stem cells with a cytokine composition, and the cytokine composition contains at least two cytokines of IL18, IL12 and IL15. Compared with exosomes secreted by human mesenchymal stem cells which are not pretreated, the exosome of the mesenchymal stem cells with the enhanced antiviral pneumonia activity, provided by the invention, has better antiviral pneumonia activity so as to be used for treating immune inflammatory reaction caused by viral pneumonia and reducing the damage of the inflammatory reaction to lung tissues; the effect of repairing tissues and organs is achieved; the exosome secreted by the pretreated human mesenchymal stem cells has the characteristics of better homogeneity, higher immunoregulatory protein content, higher exosome particle content and the like; the compound can be applied to preparation of drugs for treating viral pneumonia or immune inflammation caused by viral pneumonia.

The invention relates to the technical field of pharmacy, and in particular to an application of rosemary extract in antiviral pneumonia medicines. In the application, the rosemary extract comprises rosmarinic acid, carnosic acid and carnosol. The invention also discloses an antiviral pneumonia medicine and a preparation method thereof. The medicine takes rosmarinic acid, carnosic acid and carnosol as active ingredients and also contains a pharmaceutically acceptable carrier to prepare a pharmaceutically acceptable dosage form. The rosemary extract components have a remarkable treatment effecton acute lung injury induced by influenza virus. The rosemary extract can significantly reduce lung index, reduce total protein content in lung, inhibit release of TNF-alpha, RANTETS and IL-6 in serum and lung, promote secretion of IL-10, significantly inhibit replication of influenza virus in lung, and reduce inflammatory injury caused by viral infection.

A method for preventing or treating nosocomial diseases, e.g., diseases caused by Pseudomonas aeruginosa, is provided. The method includes administering to a susceptible human a specified dose of a bispecific antibody that that specifically binds Pseudomonas aeruginosa Psl and PcrV.